Has Michael Zgoda, MD received payments from drug or device companies?

Yes. Drug and device makers reported $28,654 in general payments to Michael Zgoda, MD across 54 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Zgoda, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Zgoda, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Zgoda, MD

Pulmonary Disease · Phoenix, AZNPI 1902910854

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $19,963 of the $28,654 with a category attached, or 69.7%. Cook Incorporated accounts for 69.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $16,503 and has fallen 76.9% since, to $3,805 in 2024. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,654in general payments, 2019–2025

Across 54 payments — averaging $530.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Cook Incorporated$20K
Intuitive Surgical$4K
Pulmonx Corporation$4K
Galvanize Therapeutics, Inc$120
Mylan Specialty L.p.$54
Insmed, Inc.$36
plus $139 from 6 others

$10,144in research payments, 2019–2025

Across 6 payments — averaging $1690.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Spiration, Inc.$10K

What the payments were for

Royalty or licence$19,96370%
Consulting fees$2,1958%
Travel & lodging$3,36512%
Food & beverage$1,6056%
Education$1,5165%
Gifts$90%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Cook Incorporated	2	$19,963
Intuitive Surgical	27	$4,230
Pulmonx Corporation	13	$4,112
Galvanize Therapeutics, Inc	1	$120
Mylan Specialty L.p.	2	$54
Insmed, Inc.	2	$36
Cook Medical LLC	1	$35
Regeneron Healthcare Solutions, Inc.	2	$33
Pfizer	1	$23
AstraZeneca	1	$18
Merck	1	$15
Mallinckrodt Enterprises LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,654 in reported general payments places this provider in the 90th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona →

Medicare billing

Part B allowed, 2024

$88,300

Medicare patients

288

Services billed

1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	40	$30,280
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	36	$16,192
Breo ElliptaFluticasone/Vilanterol	36	$13,723
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	24	$2,946
Albuterol Sulfate HfaAlbuterol Sulfate	52	$1,376
Azithromycin	28	$355
Prednisone	66	$234
Fluticasone Propionate	12	$183

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Phoenix

Rajat WaliaPhoenix$748K
Brian PorvinPhoenix$276K
Abid KhokarPhoenix$262K
Tony HodgesPhoenix$248K
Mark GotfriedPhoenix$196K
Rajeev SaggarPhoenix$161K
Gregory AhearnPhoenix$144K
Jagruti PatelPhoenix$141K
Ali SaeedPhoenix$138K
Ramit SharmaPhoenix$65K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →